Open access
Sep 2026
Preclinical and First‐In‐Human Evaluation of Ribupatide (HRS9531), a Dual GLP‐1/GIP Receptor Agonist
This study assessed the preclinical and clinical pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of ribupatide (HRS9531), a novel dual agonist of glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptors.
K. He, Yi-Lin Wei, Heng-Li Zhao et al.
· Diabetes, obesity and metabo... · 0 citations